期刊
ANNUAL REVIEW OF VIROLOGY, VOL 2
卷 2, 期 -, 页码 599-618出版社
ANNUAL REVIEWS
DOI: 10.1146/annurev-virology-100114-054915
关键词
bacteriophage therapy; biotechnology; phage therapy clinical trial; stability; pharmaceutical dosage formulation
类别
Recently, a number of phage therapy phase I and II safety trials have been concluded, showing no notable safety concerns associated with the use of phage. Though hurdles for efficient treatment remain, these trials hold promise for future phase III clinical trials. Interestingly, most phage formulations used in these clinical trials are straightforward phage suspensions, and not much research has focused on the processing of phage cocktails in specific pharmaceutical dosage forms. Additional research on formulation strategies and the stability of phage-based drugs will be of key importance, especially with phage therapy advancing toward phase III clinical trials.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据